Risk factors for in situ breast cancer.

作者: A Paganini-Hill , M P Longnecker , L Bernstein , R K Ross , S M Enger

DOI:

关键词: GynecologyBreast cancerBreast carcinomaMass screeningCancer registryCancerOdds ratioObstetricsCarcinoma in situMedicineHormone replacement therapy (menopause)

摘要: Few data exist on risk factors for in situ breast carcinoma. We examined carcinoma from two population-based case-control studies of cancer conducted among female residents Los Angeles County. Cases with or invasive disease were identified through the registry Country 1980s. included all cases ages 40 years younger diagnosed over a 5.5-year period and 55-64 3-year period. Control subjects individually matched to by age (+/-3 years), neighborhood residence, and, controls, parity (nulliparous versus parous). The analysis 233 cancer, 2057 2203 controls. Odds ratios (ORs) 95% confidence intervals (CIs) adjusted screening mammography established factors. In general, similar those this population. premenopausal women, however, decreased increasing body mass index, whereas disease, index was unrelated risk. addition, postmenopausal women known at menopause, use unopposed estrogen replacement therapy associated increased [OR ever alone 1.60 (95% CI, 1.00-2.58)], OR 1.23 1.00-1.50). A difference seen combined hormone therapy. Unmeasured users compared nonusers could account some association use.

参考文章(19)
Joseph Chu, Abraham I. Schweid, Noel S. Weiss, Survival among women with endometrial cancer: A comparison of estrogen users and nonusers American Journal of Obstetrics and Gynecology. ,vol. 143, pp. 569- 573 ,(1982) , 10.1016/0002-9378(82)90549-X
Janet L. Stanford, David B. Thomas, Exogenous Progestins and Breast Cancer Epidemiologic Reviews. ,vol. 15, pp. 98- 107 ,(1993) , 10.1093/OXFORDJOURNALS.EPIREV.A036120
Jennifer L. Kelsey, Breast Cancer Epidemiology: Summary and Future Directions Epidemiologic Reviews. ,vol. 15, pp. 256- 263 ,(1993) , 10.1093/OXFORDJOURNALS.EPIREV.A036112
Louise A. Brinton, Catherine Schairer, Estrogen Replacement Therapy and Breast Cancer Risk Epidemiologic Reviews. ,vol. 15, pp. 66- 79 ,(1993) , 10.1093/OXFORDJOURNALS.EPIREV.A036117
Malcolm C. Pike, Darcy V. Spicer, Laila Dahmoush, Michael F. Press, Estrogens, Progestogens, Normal Breast Cell Proliferation, and Breast Cancer Risk Epidemiologic Reviews. ,vol. 15, pp. 17- 35 ,(1993) , 10.1093/OXFORDJOURNALS.EPIREV.A036102
Carol A Derby, Anne Lamont Hume, Marilyn McFarland Barbour, Janice B McPhillips, Thomas M Lasater, Richard A Carleton, None, Correlates of Postmenopausal Estrogen Use and Trends through the 1980s in Two Southeastern New England Communities American Journal of Epidemiology. ,vol. 137, pp. 1125- 1135 ,(1993) , 10.1093/OXFORDJOURNALS.AJE.A116616
Janet L. Stanford, Noel S. Weiss, Lynda F. Voight, Janet R. Daling, Laurel A. Habel, Mary Anne Rossing, Combined Estrogen and Progestin Hormone Replacement Therapy in Relation to Risk of Breast Cancer in Middle-Aged Women Obstetrical & Gynecological Survey. ,vol. 51, pp. 32- 34 ,(1996) , 10.1097/00006254-199601000-00017
Virginia L Ernster, John Barclay, Karla Kerlikowske, Deborah Grady, I Craig Henderson, Incidence of and Treatment for Ductal Carcinoma In Situ of the Breast JAMA: The Journal of the American Medical Association. ,vol. 275, pp. 913- 918 ,(1996) , 10.1001/JAMA.1996.03530360023033
C. Hsieh, M. Pavia, M. Lambe, S.-J. Lan, G.A. Colditz, A. Ekbom, H.-O. Adami, D. Trichopoulos, W.C. Willett, Dual effect of parity on breast cancer risk European Journal of Cancer. ,vol. 30, pp. 969- 973 ,(1994) , 10.1016/0959-8049(94)90125-2